CD19 and myasthenia gravis: Recent case reports of the therapeutic success of anti-CD19 CAR T cells in autoimmune disorders such as systemic lupus erythematosus and myasthenia gravis (MG) (2–4), among others, have generated interest in expanding the applications of the technology to treat a broad range of B cell–mediated diseases.